中文名 | 盐霉素钠 |
英文名 | Salinomycin sodium salt |
别名 | 盐霉素钠 盐霉素钠盐 沙利霉素钠 沙利诺马辛 盐霉素预混 盐霉素钠盐 标准品 盐霉素 单钠盐 水合物 盐霉素溶液, 100PPM 盐霉素SV钠盐的五个半水合物 |
英文别名 | Salinomycin sodium Salinomycin-Natrium Salinomycin sodium salt Salinomycin, Sodium Salt Salinomycin sodium premix Salinomycin, monosodium salt SALINOMYCIN SODIUM SALT 2.5-HYDRATE salinomycin monosodium salt hydrate Salinomycin hydrate monosodium salt SALINOMYCIN SV SODIUM SALT 2,5-HYDRATE (2R)-2-[(5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-Ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5.3]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid |
CAS | 55721-31-8 |
EINECS | 611-309-0 |
化学式 | C42H71NaO12 |
分子量 | 791 |
InChI | InChI=1/C42H70O11.Na/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33;/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47);/q;+1/p-1/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-;/m0./s1 |
熔点 | 140-142° |
比旋光度 | D25 -37° (c = 1 in ethanol) |
溶解度 | 溶于DMSO。 |
存储条件 | APPROX 4°C |
稳定性 | 从提供的购买之日起稳定2年。在DMSO中的溶液可以在-20 ° 储存长达3个月。 |
外观 | 整洁 |
颜色 | White |
Merck | 13,8415 |
BRN | 4901827 |
物化性质 | 白色或淡黄色结晶性粉末,微有特异臭,熔点140-142℃。易溶于丙酮、三氯甲烷、苯、乙酸乙酯、乙醚和甲醇,几乎不溶于水。大白鼠经口LD5070-100mg/kg,小白鼠经口LD5050mg/kg,鸡LD50150mg/kg。 |
体外研究 | Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC 50 24h : 13.8 μM, IC 50 48h : 6.888 μM and IC 50 72h : 4.382 μM for A2780 cell lines), (IC 50 24h : 12.7 μM, IC 50 48h : 9.869 μM and IC 50 72h : 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor. |
体内研究 | Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice. |
危险品标志 | T - 有毒物品 |
风险术语 | 25 - 吞食有毒。 |
安全术语 | 45 - 若发生事故或感不适,立即就医(可能的话,出示其标签)。 |
危险品运输编号 | 2811 |
WGK Germany | 3 |
Hazard Class | 6.1 |
Packing Group | III |
上游原料 | 酒石酸铵 |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!